RxDoctor Payments Data

Elizabeth Cull

Family · Louisville, KYNPI 1356677678

Payments from drug & device makers

$2,749in general payments, 2019–2025

Across 80 payments — averaging $34.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$747
  • Novo Nordisk$453
  • Phathom Pharmaceuticals, Inc.$250
  • Biohaven Pharmaceuticals, Inc.$185
  • Bayer$150
  • Abiomed$149
  • plus $814 from 15 others

What the payments were for

  • Food & beverage$2,749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,749 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$36,729
Medicare patients
113
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$28,093
MounjaroTirzepatide16$16,191
Breo ElliptaFluticasone/Vilanterol13$8,881
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,938
Albuterol Sulfate HfaAlbuterol Sulfate34$1,686
SynthroidLevothyroxine Sodium21$1,152
Tramadol Hcl ErTramadol Hcl13$982
Venlafaxine Hcl ErVenlafaxine Hcl16$895
Levothyroxine Sodium101$786
Atorvastatin Calcium133$758
Losartan Potassium82$621
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$478
Potassium Chloride28$473
Bupropion XlBupropion Hcl26$425
Sertraline Hcl38$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$453$28,09322 claims
GSKBreo Ellipta$13$8,88113 claims
AbbVieSynthroid$27$1,15221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →